Drug Discovery
Jul 15, 2026
OpenAI's Miles Wang Raising $2B for AI Drug Discovery
Miles Wang, a researcher at OpenAI, is in early talks to spin out a new AI-powered drug discovery startup at a reported $2 billion valuation. The discussions signal continued investor appetite for applying frontier AI to life sciences. If closed, the deal would be one of the largest seed-stage bets in the biotech-AI crossover space.
AI
Biotech
Startups
Jul 12, 2026
Reed Jobs's Biotech Startup Is Moving Fast
Three years after launching Yosemite, Reed Jobs is all-in on biotech and AI. His firm has grown to 17 people, patent cliffs are opening new drug opportunities, and AI has become central to how Yosemite operates.
AI
biotech
drug discovery
Jul 1, 2026
Anthropic Launches Claude Science for Researchers
Anthropic unveiled Claude Science, a flagship AI product targeting drug discovery and computational biology. Meanwhile, California's methane-to-gas subsidy program is drawing scrutiny for potentially locking in more warming than it prevents.
Anthropic
Claude
AI for Science